Form 4: Cargo Therapeutics CEO Gina Chapman Executes Stock Option and Sells Shares

Gina Chapman, President and CEO of Cargo Therapeutics, exercised stock options and sold shares of common stock on September 18 and 19, 2024, according to a Form 4 filing with the SEC.

Summary

• Gina Chapman, the President and CEO of Cargo Therapeutics, exercised stock options to acquire shares of common stock on September 18 and 19, 2024.
• On September 18, 2024, she acquired 7,166 shares at a price of $5.03 per share and sold 7,166 shares at a weighted average price of $25.0872.
• On September 19, 2024, she acquired 2,975 shares at a price of $5.03 per share and sold 2,975 shares at a weighted average price of $25.0275.
• The sales were executed pursuant to a Rule 10b5-1 trading plan adopted on March 25, 2024.
• Following these transactions, Chapman directly owns 103,905 shares of common stock and holds options to purchase 549,515 shares.

Sentiment

Score: 5

Explanation: Neutral sentiment. This is a standard Form 4 filing indicating insider transactions executed under a pre-existing trading plan. It doesn't inherently suggest positive or negative news about the company.

Industry Context

This filing is a routine disclosure of insider transactions. It's common for executives to have pre-arranged trading plans (Rule 10b5-1) to avoid accusations of trading on inside information.

Comparison to Industry Standards

• Executive compensation packages often include stock options, aligning management's interests with shareholders.
• Rule 10b5-1 trading plans are a standard practice among public company executives to manage their stock sales in a transparent and compliant manner.
• The vesting schedule of the options (25% after one year, then monthly) is a typical vesting arrangement.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the pre-planned nature of the sales mitigates concerns about insider information being used.

Key Dates